Our 2024 Partners

lunit logo

Expertise Partner: Lunit

Lunit develops AI-powered medical image analysis software via cutting-edge deep learning technology. Our Lunit SCOPE product suite helps researchers and clinicians make accurate and efficient decisions through data-driven imaging biomarkers. Lunit SCOPE IO is our AI-powered analyzer of the tumor microenvironment, purely from H&E, for quantitative immune phenotyping and beyond. Peer reviewed studies employing SCOPE IO have been published in the Journal of Clinical Oncology, Clinical Cancer Research, NPJ Precision Oncology, and more. Lunit SCOPE IHC is our AI-powered analyzer of IHC targets including PD-L1, HER2, and more. Lunit SCOPE IHC currently powers all PD-L1 scoring for Guardant Health's Galaxy PD-L1 tissue testing. Lunit works with the world's leading biopharmaceutical companies, CROs, and clinical labs to develop and deploy the next generation of oncology therapeutic biomarkers.



Expertise Partner: Nucleai

Nucleai is the leading AI-powered spatial biomarker company, driving innovation at the intersection of technology and healthcare. Leveraging military intelligence-grade geospatial analytical methods, it intercepts, interprets, and analyzes complex cellular conversations and spatially oriented interactions within tissue samples, translating them into actionable insights. Nucleai’s platform empowers pathologists and researchers with an AI-powered data-rich action plan, paving the way for more informed decisions in the development of bi-specifics, antibody-drug conjugates (ADCs), and immunotherapy. Nucleai's investors include Section 32, Sanofi, Vertex Ventures, M Ventures, and Debioopharm. It is headquartered in Israel and Chicago.


Expertise Partner: AIRA Matrix

AIRA Matrix provides Artificial Intelligence solutions for Clinical and Life Sciences
applications. Our products and services improve efficiency, diagnostic accuracy, and turn
around times in pathology laboratory workflows. Our diagnostic, prognostic, and predictive
solutions for cancer care aid disease stratification and enable management protocols tailored
to improve treatment outcomes.